tallimustine

Tallimustine is a benzoyl mustard derivative of distamycin A and functions as an alkylating agent with antitumor activity. It binds selectively to the minor groove of DNA, particularly at A-T rich regions, and alkylates the N3 position of adenine in a highly sequence-specific manner. This interaction prevents DNA replication, inhibits cellular proliferation, and induces apoptosis. Unlike other nitrogen mustards, tallimustine does not alkylate guanine-N7 in the major groove of DNA, which may contribute to its selectivity. Tallimustine was investigated for use in treating tumors—including advanced solid tumors and colorectal cancer—but development was discontinued due to severe myelotoxicity (notably neutropenia). The drug reached phase II clinical trials before being abandoned in favor of derivatives with improved safety profiles[1][2][4][6][8].

Other names

talimustine